-
Posted by
Two Blokes Jun 6 -
Filed in
Stock
-
2 views
- Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL\u00ae gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds.
